# Berodual® Respimat® Versus Berodual® Metered Aerosol (MA) Inhaler in Patients With Asthma, Chronic Obstructive Pulmonary Disease, or Mixed Condition

> **NCT02173795** · PHASE3 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 245 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive
- Asthma

## Interventions

- **DRUG:** Berodual® Respimat®
- **DRUG:** Berodual® MA HFA

## Key facts

- **NCT ID:** NCT02173795
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-10
- **Primary completion:** 2003-06
- **Final completion:** —
- **Target enrollment:** 245 (ACTUAL)
- **Last updated:** 2014-07-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02173795

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02173795, "Berodual® Respimat® Versus Berodual® Metered Aerosol (MA) Inhaler in Patients With Asthma, Chronic Obstructive Pulmonary Disease, or Mixed Condition". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02173795. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*